Silence Therapeutics' Divesiran Shows Durable Efficacy in Polycythemia Vera Phase 1 Trial
Event summary
- Silence Therapeutics presented follow-up data from the Phase 1 SANRECO study at EHA 2026, showing durable efficacy of divesiran in polycythemia vera patients.
- Phlebotomy use reduced from 80 in six months prior to treatment to just 5 during active treatment and 4 in the 16-week follow-up period.
- Median time to first phlebotomy was 287 days among 14 patients with further follow-up data.
- Divesiran was well tolerated with no dose-limiting toxicities observed.
- Topline data from the ongoing Phase 2 SANRECO study expected in August 2026.
The big picture
Silence Therapeutics' positive Phase 1 data for divesiran comes at a time when siRNA therapies are gaining traction in the treatment of rare diseases. The durable efficacy and reduced phlebotomy burden observed in the study could position divesiran as a potential game-changer in the polycythemia vera market, which currently lacks targeted therapies. The upcoming Phase 2 topline data will be critical in assessing the commercial potential of this novel approach.
What we're watching
- Clinical Validation
- Whether the durable efficacy and safety profile of divesiran observed in Phase 1 will be confirmed in the larger Phase 2 trial.
- Regulatory Pathway
- The pace at which Silence Therapeutics can advance divesiran through regulatory approvals given its Fast Track and Orphan Drug designations.
- Market Differentiation
- How divesiran's potential best-in-class profile will position it against existing treatments for polycythemia vera.
Related topics